Brief Summary
This podcast episode of "This Week in Cardiology" covers a range of topics including listener feedback on statin therapy, the risks associated with urgent AF ablations, the effectiveness of AF ablation for stroke reduction, the accuracy of implantable loop recorders (ILRs), and heart failure management in patients with serious diseases like cancer. The key takeaways include the importance of personalized discussions in medication decisions, caution against urgent AF ablations due to higher complication rates, the limited evidence supporting AF ablation for stroke reduction, the variable accuracy of ILRs, and the need for tailored heart failure therapy in patients with life-limiting conditions.
- Personalized discussions are crucial for medication decisions.
- Urgent AF ablations carry higher complication risks.
- AF ablation has limited evidence for stroke reduction.
- ILRs have variable accuracy and require careful monitoring.
- Heart failure therapy should be tailored in patients with serious diseases.
Listener Feedback on Statin Therapy
Dr. Kuma Foby from Rush University in Chicago, provided feedback on a previous discussion about a JAMA Internal Medicine letter regarding patient preferences for statin therapy. The original survey found that many individuals would refuse statins even with a significant risk reduction. Dr. Foby pointed out that the survey only included individuals who had never been on statins, potentially skewing the results towards "minimizers." He emphasized the importance of personalized discussions between physicians and patients, suggesting that patients are more likely to accept medication when recommended by a trusted doctor. This highlights the concept of external validity, where evidence from controlled studies may not always translate directly to real-world practice.
Urgent AF Ablations: Risks and Considerations
An observational study published in JACC EP examined the use and safety of urgent AF ablation in the US, which is defined as AF ablation performed on patients hospitalized for reasons other than AF. The study, using data from an AF ablation registry from 2016 to 2023, compared urgent AF ablation cases to elective cases. The results indicated that urgent AF ablation is associated with a significantly higher rate of procedure-related complications compared to elective AF ablation (4.9% vs. 2.4%). Urgent AF ablations were more common in patients with comorbid conditions and were increasingly performed over the study period. The author suggests caution and advises against urgent AF ablation in most cases, recommending that the primary condition be treated first, followed by elective AF ablation after stabilization.
AF Ablation as a Stroke Reducing Therapy: The STABLED RCT
The STABLED RCT, published in JAMA Neurology, investigated whether adding AF ablation to DOAC therapy reduces the risk of recurrent ischemic stroke, systemic embolism, all-cause death, or heart failure hospitalization in patients with AF and recent stroke history. The trial randomized 250 patients to either DOAC alone or DOAC plus AF ablation. The primary composite endpoint occurred in 22 patients in both groups, with no significant difference between the arms. Major bleeding was more frequent in the ablation arm, although not statistically significant. The authors concluded that AF ablation did not significantly reduce the risk of the primary composite endpoint. The author argues that the trial was underpowered due to an overly optimistic assumption about the risk reduction from ablation, significant crossover between the arms, and the effectiveness of DOAC therapy alone. AF ablation should be considered to improve quality of life by reducing AF burden, not as a stroke reducer.
ILR Loop Recorder Accuracy
A study published in JACC EP evaluated the accuracy of implantable loop recorders (ILRs) from Medtronic, Boston Scientific, Biotronic, and Abbott in detecting arrhythmias. The study analyzed a database of ECG-verified episodes from 6,700 patients, selecting a random sample of 40 patients for detailed analysis. The results showed variable accuracy among devices, with Boston Scientific having the highest positive predictive value for AF detection, while Biotronic had the lowest. False positive rates for AF detection were high overall, with Biotronic having the highest rate at 89%. The author emphasizes the importance of attention to detail during insertion and review of tracings to minimize false positives. Programming a longer AF detection time is also recommended to reduce the detection of benign PACs.
Heart Failure Management in the Setting of Serious Disease
The EMPATIC trial, published in the European Heart Journal, assessed the impact of typical heart failure therapy in patients with both progressive heart failure and advanced cancer. The trial randomized 93 patients with stage 4 solid tumors, low life expectancy, and functional limitations from heart failure to either heart failure therapy (including sacubitril/valsartan, empagliflozin, ivabradine, furosemide, and/or spironolactone) or placebo. The primary endpoint, days alive and able to wash oneself, did not differ significantly between the groups. Overall mortality was 32% at 30 days and did not differ between groups. The author supports the trial for gathering empirical data and highlights that guideline-directed heart failure therapy is proven beneficial in relatively healthy patients, not those with life-limiting conditions. The author suggests prioritizing quality of life and avoiding non-beneficial heart failure interventions in patients with serious diseases like cancer, dementia, CKD, COPD, and frailty.
